Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-5 reverse stock split effective March 27, 2026, which will affect its issued and outstanding common stock as well as its authorized common stock [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 5 shares of common stock into 1 share, with fractional shares being rounded up to the next whole share for registered holders [2]. - Beneficial holders in street name will receive a cash payment for fractional shares, determined by their brokers [2]. - Post-split, the company will have approximately 1,615,419 shares of common stock issued and outstanding, and the authorized shares will be adjusted to 50,000,000 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [3]. - The company operates four fertility clinics in the U.S. and aims to provide a more natural and affordable experience through its intravaginal culture (IVC) procedure [3]. - The IVC procedure is positioned as a cost-effective alternative to traditional IVF, offering comparable results at a lower price [3].

Summary of Progyny Conference Call Company Overview - **Company**: Progyny - **Industry**: Fertility and IVF Benefits - **Position**: One of the largest publicly traded fertility IVF benefit partners Key Points and Arguments Financial Performance - **Fourth Quarter Earnings**: Noted a reduction of 400,000 eligible lives due to administrative corrections from employer clients [1][2] - **Utilization Rate**: Maintained a tight range of 1.03 to 1.09 over the years, focusing on actual utilization rather than just eligible lives [3][4] - **Attrition**: Primarily from lower-utilizing clients, while new sign-ons from the selling season are expected to be better utilizers [5][6] Utilization Trends - **Utilization Timing**: New cohorts typically start utilizing benefits in Q2 through Q4 after initial consultations in Q1 [16][17] - **Consultation to Treatment Cycle**: Average of 1.8 retrievals per live birth, indicating multiple cycles may occur before a transfer [17][18] Progyny Select Program - **Launch Strategy**: The fully insured program is set to go live in 2027, with current efforts focused on signing up distributors and training brokers [23][29] - **Sales Model**: Commission-based structure minimizes upfront expenses, with revenue tied to client renewals [30][32] - **Risk Mitigation**: Designed to address small group employers, with underwriting based on extensive data from smaller clients [35][37] Market Opportunities and Challenges - **State Mandates**: California's IVF mandate could significantly increase volumes, but competition remains a challenge [48][50] - **Education and Awareness**: Emphasis on educating brokers and distribution partners about the benefits of Progyny's offerings [51][52] Competitive Landscape - **Market Position**: Despite competition, Progyny continues to win the majority of clients, with some competitors facing financial challenges [80][81] - **Investment in Offerings**: Ongoing investments to enhance services and maintain a competitive edge [81] Technology and Data Utilization - **AI and Data Integration**: Investments in technology aim to improve client experiences and outcomes by automating tasks and providing better recommendations [75][78] Progyny Rx - **Patient Assistance Program**: Progyny Rx is not designed for those with coverage, focusing instead on those without insurance [60][62][70] - **Impact on Business**: No expected impact on Progyny's business from the Progyny Rx program as it serves a different market segment [73] Additional Important Insights - **Retention Rates**: High retention rates (99%) attributed to comprehensive program management for clients [42] - **Market Dynamics**: The competitive environment remains stable, with no significant increase in competition noted [81] This summary encapsulates the key discussions and insights from the conference call, highlighting Progyny's strategic focus, market positioning, and operational dynamics.

Summary of Progyny FY Conference Call (March 11, 2026) Company Overview - **Company**: Progyny (NasdaqGS: PGNY) - **Industry**: Fertility Benefits and Assisted Reproductive Technology Key Points Financial Performance - **4Q Performance**: Progyny exceeded guidance with a growth of approximately 20% in 2025, excluding one customer [1] - **Client Retention**: The company achieved a 99% client retention rate, with about 30% of clients expanding their benefits [2] - **Revenue Guidance**: The company has guided for a revenue growth of about 7% for the year, aligned with membership growth [34] Membership and Utilization - **Membership Estimate**: The estimated number of lives for 2026 was revised to 7.2 million, attributed to administrative updates rather than layoffs or macroeconomic factors [3] - **Utilization Rate**: The historical utilization rate has been consistent, ending last year at 1.04%. The company expects to remain within the low to middle of its historical utilization range for the current year [8] - **Impact of Macroeconomic Factors**: Utilization is primarily driven by the biological need for fertility assistance rather than macroeconomic conditions, such as tax refunds [10][11] Competitive Landscape - **Market Position**: Progyny competes more with managed care organizations (MCOs) that offer fertility benefits rather than standalone competitors. The company maintains a high win rate when clients decide to add fertility benefits [13][17] - **MCO Engagement**: MCOs have not become more aggressive in the fertility space due to lack of financial incentives, as they do not profit from increased utilization of fertility benefits [18][19] Product Expansion and Opportunities - **Client Expansion**: 30% of clients added to their offerings, including cycles and new products like menopause and postpartum support [20][22] - **Fully Insured Market**: Progyny is expanding into the fully insured market, addressing the needs of small employers who typically lack access to fertility benefits [24][25] - **Sales Cycle**: The sales cycle for fully insured buyers aligns with traditional cycles, with renewals generally occurring in the fourth quarter [28] Risk Management - **Contract Duration**: Fully insured buyers operate on annual contracts, allowing for premium adjustments based on experience [31] - **Utilization Risk**: Initial utilization risk exists with smaller populations, but as the risk pool grows, it will be managed similarly to self-insured populations [32] Future Outlook - **Growth Expectations**: The company expects to add approximately 1 million lives annually, with potential incremental contributions from new products [42] - **Long-term Margin Opportunities**: Future margin expansion is anticipated as investments taper off and operational efficiencies improve, particularly through AI and care management enhancements [39][40] Additional Insights - **Pipeline Status**: The current pipeline is primarily carryover from previous years, with positive expectations for the upcoming sales season [41] - **Market Positioning**: Progyny is well-positioned to expand its addressable market and maintain a competitive edge over standalone competitors and MCOs [42] This summary encapsulates the key insights and data points from the Progyny FY Conference Call, highlighting the company's performance, market dynamics, and future strategies.

Summary of Progyny (NasdaqGS:PGNY) 2026 Conference Call Company Overview - **Company**: Progyny, a healthcare technology company specializing in fertility benefits and services Key Points Industry Dynamics - **Healthcare Sector Growth**: Progyny has seen a significant increase in healthcare clients, now representing the largest percentage of their industry exposure, driven by the need for fertility support among large hospital systems and healthcare providers [38][44] - **Fertility Support Demand**: The company emphasizes the importance of fertility benefits, especially in industries with a large female workforce, which has led to a competitive advantage in attracting healthcare clients [44][45] Financial Performance - **2025 Utilization Trends**: The company reported improving utilization rates in 2025, with consistent consumption patterns observed throughout the year. Utilization is defined as the number of members engaging with the services [5][6][10] - **Revenue Model**: Progyny operates on a consumption model rather than a per-member-per-month model, meaning revenue is driven by actual service usage rather than membership counts [12][16][24] Membership and Client Dynamics - **Membership Adjustments**: The company has experienced variability in membership counts, which has not negatively impacted revenue due to the nature of their consumption model. They maintain a hands-off approach in addressing discrepancies in client-reported member counts [12][15][24] - **New Client Acquisition**: Approximately 50% of new clients are adopting fertility benefits for the first time, while the other half are transitioning from traditional carrier benefits [46] Product and Service Innovations - **Smart Cycle Utilization**: The Smart Cycle model allows for flexible treatment options, and clients are increasingly opting for more comprehensive coverage, including unlimited Smart Cycles [49] - **New Product Launches**: Progyny has introduced menopause and pregnancy/postpartum products, which have seen positive adoption rates. The company is focused on increasing awareness and utilization of these services [63][64] Technology and AI Integration - **IT Investments**: Progyny is investing in IT systems to enhance member engagement and improve service delivery. The focus is on maintaining a human touch in patient care while leveraging AI for operational efficiencies [51][52][53] - **AI's Role**: The company views AI as a tool for improving business operations rather than replacing human roles, particularly in patient care advocacy [51][53] Future Outlook - **Progyny Select Launch**: The new Progyny Select product aims to provide fertility benefits to smaller companies, with positive feedback from initial market testing. The company is cautious about setting expectations for its first year [72][74] - **Risk Management**: The company has designed the Progyny Select product to mitigate risks associated with underwriting, including fixed Smart Cycle limits and a risk premium in pricing [78][82] Financial Strategy - **Share Buyback Program**: Progyny is actively engaged in a share buyback program, with a focus on returning capital to shareholders while managing growth and operational needs [91][92] Additional Insights - **Pharmacy Management**: The company emphasizes the importance of managing drug costs and usage effectively, highlighting the potential for significant savings through their holistic approach to fertility services [87][88] This summary encapsulates the key insights and strategic directions discussed during the Progyny conference call, reflecting the company's focus on growth, innovation, and client satisfaction in the fertility benefits sector.

Core Viewpoint - INVO Fertility, Inc. has adopted time-lapse incubation technology at its Wisconsin clinic, reflecting its commitment to high-quality patient care and innovative solutions in the fertility sector [1][3]. Group 1: Technology Adoption - The integration of time-lapse incubation technology enhances the tools available to embryology teams, aligning with the company's focus on quality and innovation in patient-centered fertility care [2][3]. - Time-lapse imaging provides detailed developmental information while embryos remain in a controlled environment, supporting informed clinical decisions [6]. Group 2: Patient Benefits - Patients benefit from advanced laboratory innovation without added complexity, receiving video records of their embryo's development, which increases engagement and understanding of the process [6]. - The use of proven, FDA-cleared technology reflects the company's focus on quality, safety, and clinical rigor, enhancing patient confidence in the treatment [6]. Group 3: Company Strategy - INVO Fertility's strategy includes expanding access to assisted reproductive technology (ART) through building, acquiring, and operating fertility clinics, including the INVO Centers [4]. - The company emphasizes responsible integration of advanced reproductive technologies that deliver meaningful value to patients and clinicians [3][4].

Chinese couples are marrying and trying for children later than in previous generations—one reason why infertility has become more of a problem. Accordingly, demand for IVF has surged https://t.co/Gn6yOE2PoX ...

Core Insights - INVO Fertility's Wisconsin Fertility Institute has joined the Progyny network, enhancing its market reach and access to employer-sponsored patients [1][2] Group 1: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to advanced reproductive treatments through the establishment and operation of fertility clinics [1][7] - The company operates four fertility clinics in the United States and is engaged in the sale and distribution of its proprietary INVOcell technology [7] Group 2: Market Expansion - Joining the Progyny network significantly increases WFI's addressable market within Wisconsin and surrounding regions, providing access to an estimated 7.2 million covered lives through over 600 employers [2][4] - Employer-sponsored fertility benefits are one of the fastest-growing segments in healthcare, as companies seek to attract and retain talent [5] Group 3: Service Offerings - Eligible patients now have in-network access to WFI's comprehensive suite of reproductive services, including diagnostic testing, in vitro fertilization (IVF), and fertility preservation [3][4] - Progyny's benefit design simplifies financial and administrative processes, reducing barriers to care and improving treatment utilization and outcomes [3] Group 4: Strategic Importance - Participation in the Progyny network enhances WFI's third-party payor mix and expands its services to a larger patient base [4] - The partnership with Progyny is viewed as a major milestone that supports INVO Fertility's broader strategy to scale its clinic platform and strengthen long-term financial performance [5][6]

Financial Data and Key Metrics Changes - Progyny reported record highs in revenue and adjusted EBITDA for 2025, with revenue reaching $1.29 billion and adjusted EBITDA at $222 million, representing increases of nearly $90 million and $28 million respectively over the midpoint of original guidance [6][19] - Operating cash flow for 2025 was a record $210 million, an increase of 17% compared to 2024 [6][21] - The company achieved a nearly 200 basis point expansion in full-year gross margin versus 2024, reflecting efficiencies in care management and service delivery [19] Business Line Data and Key Metrics Changes - Member engagement remained healthy, with utilization and consumption of ART cycles per unique utilizer pacing favorably against guidance [18] - 30% of the client base expanded their benefits with Progyny for 2026 through upsells and service enhancements, providing access to new services for over 2.7 million members [10] Market Data and Key Metrics Changes - The self-insured market is expected to continue comprising the majority of new lives added, with opportunities to broaden the target market to smaller employers [12] - The healthcare industry, as the largest sector for Progyny, has shown resilience against macro uncertainties over the past five years [11] Company Strategy and Development Direction - Progyny is focusing on member and client satisfaction, which has led to nearly 100% client retention, including all largest employers [7] - The company is launching Progyny Select to address the needs of smaller employers, providing a fixed premium product that minimizes financial risk [13][14] - Investments in technology, including AI, are aimed at enhancing member experience and driving efficiencies [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with considerable momentum, driven by strong demand for family building and women's health services [11] - The guidance for 2026 anticipates 7.2 million covered lives, reflecting a net reduction due to administrative updates rather than workforce reductions [23] - The company expects revenue growth of 5.1% to 9% for 2026, with adjusted EBITDA projected between $224 million and $239 million [29][30] Other Important Information - The departure of the President at the end of 2025 resulted in an incremental $7.7 million in stock-based compensation expense [25] - The company repurchased over 3.3 million shares for nearly $84 million under its share repurchase program [22] Q&A Session Summary Question: Clarification on membership outlook for 2026 - Management clarified that the changes in membership figures relate to existing clients and are due to administrative updates rather than new client issues [33][34] Question: Discussion on Progyny Rx model and economics - Management noted no pushback from employers regarding the Progyny Rx model and emphasized the value delivered through integrated programs [36][37] Question: Strategy and pricing for Progyny Select - Management explained that pricing for Progyny Select is based on experience data from smaller clients, with guardrails in place to manage risk [41][44] Question: Contribution from maternal health services - Management indicated that while maternal health services are growing, they are not yet material but serve as a value add [55] Question: Expectations for CapEx and cash flow conversion - Management anticipates a step-up in CapEx for 2026 but not a doubling, with a cash flow conversion rate of approximately 75% from adjusted EBITDA [82][84]

Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]

Core Viewpoint - INVO Fertility, Inc. is positioned for growth with a strengthened fundamental position, focusing on operational progress, disciplined capital management, and a clear growth strategy [3][4][21]. Operational Progress - The company has three operational fertility clinics generating positive cash flow, marking a critical milestone in achieving profitability at the clinic level [5]. - INVO Fertility is nearing the acquisition of a fourth clinic in Indianapolis, which will diversify revenue and enhance earnings power [6]. Financial Performance - The combined pro forma annualized revenue run rate from all clinics is approximately $9 million, providing a strong baseline for growth [7]. - The company has simplified and strengthened its capital structure, with recent financing issued at a fixed price of $1.59, enhancing clarity and alignment for shareholders [16][17]. Growth Strategy - Organic growth is a key component of the strategy, focusing on increasing patient volumes and optimizing treatment pathways [8][9]. - Acquisitions are a cornerstone of growth, with a robust pipeline of potential targets under evaluation, emphasizing clinics with strong reputations and operational improvement opportunities [10][11][12]. Market Environment - Recent executive actions support federal access to IVF and fertility treatments, potentially increasing patient demand and utilization of fertility services [13]. - The company anticipates strong growth in 2026, driven by acquisitions and organic expansion, addressing the rising global infertility rates and limited access to affordable services [14][15]. Future Outlook - INVO Fertility is positioned for a higher-growth phase with a stabilized operational base and a strong balance sheet, aiming to build a scalable platform for sustained growth [19][21].